sepetoprost
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT01508988)
Timeline
Indications
Mechanism of action
- Prostanoid FP receptorAGONIST
PTGFR agonist
- Prostanoid EP3 receptorAGONIST
PTGER3 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ono-9054
- ono-9054
- propan-2-yl 4-(6-(4-(2,5-difluorophenoxy)-3-hydroxybut-1-en-1-yl)-7-hydroxyoctahydro-2h-cyclopenta(b)oxepin-3-yl)butanoate
- sepetoprost
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02083289 | Phase 2 | May 1, 2014 | Ono Pharmaceuticals |
| NCT01670266 | Phase 1 | Aug 1, 2012 | Ono Pharmaceuticals |
| NCT01508988 | Phase 1 | Jan 1, 2012 | Ono Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ono Pharmaceuticals | For profit | 3 | 3 | 2 | 2012 |
1 organizations
Page 1 / 1